Download Library

 
 
 
Download Library
Document Type
Efficacy of DRd Versus Rd in Relapsed or Refractory MM Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux - ASH presentation - December 2016 (Usmani)
PDF
1.4 MB
Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with MM Who Have Received 1 or More Prior Lines of Therapy - ASH poster - December 2016 (Xu)
PDF
237.7 KB
Comparative Effectiveness of Daratumumab Versus a Real-World Historical Control in Heavily Pretreated and Highly Refractory MM - ASH poster - December 2016 (Hájek)
PDF
308.5 KB
Efficacy of DRd Versus Rd for Relapsed or Refractory MM: Updated Analysis of Pollux - ASH presentation - December 2016 (Moreau)
PDF
1.0 MB
Evaluation of MRD in Relapsed/Refractory MM Patients Treated with Daratumumab in Combination with Rd or Vd - ASH presentation - December 2016 (Avet-Loiseau)
PDF
2.6 MB
Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage- Induced ADCP - ASH poster - December 2016 (Rigalou)
PDF
1.2 MB
Results of an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH poster - December 2016 (Chari)
PDF
596.1 KB
Overcoming the interference of daratumumab with Immunofixation Electrophoresis using an industry-developed DIRA test - ASH poster - December 2016 (Irimia)
PDF
1.1 MB
Jefferies London Healthcare Conference, London, UK - November 2016
PDF
1.8 MB
Capital Markets Day Presentation - November 2016
PDF
9.0 MB
Frontline Ofatumumab in Combination with Hyper-CVAD for Patients with CD-20 Positive ALL: Interim Result of a Phase II Trial - ASH abstract - November 2016 (Sasaki)
URL
N/A
Cost-Effectiveness Analysis of Ofatumumab as a Treatment for Relapsed CLL in the United States - ASH abstract - November 2016 (Tremblay)
URL
N/A
Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with MM Who Have Received 1 or More Prior Lines of Therapy - ASH abstract - November 2016 (Xu)
URL
N/A
Efficacy of DRd Versus Rd in Relapsed or Refractory MM Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux - ASH abstract - November 2016 (Usmani)
URL
N/A
Phase 1b Study to Assess Subcutaneous Daratumumab in pts with Relapsed or Refractory MM (PAVO) - ASH abstract - November 2016 (Usmani)
URL
N/A
Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage- Induced ADCP - ASH abstract - November 2016 (Rigalou)
URL
N/A
Efficacy of DRd Versus Rd for Relapsed or Refractory MM: Updated Analysis of Pollux - ASH abstract - November 2016 (Moreau)
URL
N/A
Efficacy of DVd Versus Vd in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor - ASH abstract - November 2016 (Mateos)
URL
N/A
Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care in pts with Heavily Pre-Treated & Highly Refractory MM - ASH abstract - November 2016 (Kumar)
URL
N/A
Comparative Effectiveness of Daratumumab Versus a Real-World Historical Control in Heavily Pretreated and Highly Refractory MM - ASH abstract - November 2016 (Hájek)
URL
N/A
DRd Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX) - ASH abstract - November 2016 (Chiu)
URL
N/A
Results of an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH abstract - November 2016 (Chari)
URL
N/A
Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH abstract - November 2016 (Chari)
URL
N/A
DVd Versus Vd Alone for Relapsed or Refractory MM Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor - ASH abstract - November 2016 (Chanan-Khan)
URL
N/A
Overcoming the interference of daratumumab with Immunofixation Electrophoresis using an industry-developed DIRA test - ASH abstract - November 2016 (Caillon)
URL
N/A

Page: First Previous
1
2
3
4
5
6
7
8
9
...
19
Next Last

 
 

There are no downloadable files available. Please check back at a later time.